<DOC>
	<DOCNO>NCT01722825</DOCNO>
	<brief_summary>The main purpose study evaluate safety side effect LY2157299 Japanese participant advanced cancer cancer spread part body .</brief_summary>
	<brief_title>Study LY2157299 Japanese Participants With Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Have histological cytological evidence diagnosis cancer advance and/or metastatic . The participant must , judgment investigator , appropriate candidate experimental therapy available standard therapy fail provide clinical benefit disease . Have presence measurable nonmeasurable disease define Response Evaluation Criteria Solid Tumors . Have performance status high equal 1 Eastern Cooperative Oncology Group scale . Have adequate hematologic , hepatic renal function . Have discontinue treatment cancer exclude palliative treatment recover acute effect therapy . Have discontinue treatment least 28 day prior enrollment experimental agent receive regulatory approval indication . Are reliable willing make available duration study willing follow study procedure . Able swallow tablet . Have estimate life expectancy , judgment investigator , permit participant complete great equal 2 cycle treatment . Males female reproductive potential : Must agree use medically approve contraceptive precaution study 4 month follow last dose study drug . Females child bear potential : Have negative urine/serum pregnancy test great equal 7 day first dose study drug must also breastfeed . If female stop breastfeed enters study , female must stop breastfeeding day first study drug administration least 30 day last administration . Have moderate severe cardiac disease : Have presence cardiac disease , include myocardial infarction within 6 month prior study entry , angina pectoris , New York Heart Association Class III/IV congestive heart failure , uncontrolled severe hypertension . Have document major electrocardiogram abnormality investigator 's discretion . Have major abnormality document echocardiography Doppler . Clinically nonsignificant abnormality exclude criterion . Have persistently elevate brain natriuretic peptide elevate Troponin I screen local laboratory test . Have predispose condition consistent development aneurysm ascend aorta aortic stress . Have history cardiac aortic surgery . Have current hematological malignancy . Have central nervous system metastasis . Have serious preexist medical condition follow ; Presence history interstitial pneumonitis Uncontrollable severe diabetes Presence serious active infection uncontrollable chronic infection Presence liver cirrhosis ChildPugh Stage B C Other serious condition judge investigator Have know positive test result human immunodeficiency virus ( HIV ) , hepatitis B surface antigen , hepatitis C antibody ( HC Ab ) . Testing required unless circumstance warrant confirmation . In opinion investigator sponsor , unsuitable inclusion study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>